Program
Antibody-drug Conjugate BL-M17D1
In Sichuan Biokin Pharmaceutical’s pipeline, HER2 ADC
. Its studies are mostly in Breast Neoplasms · Esophageal Neoplasms, led by Sichuan Biokin Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Biokin Pharmaceutical | 32 open or running | phase 1since Jul 8, 2024 | Jul 8, 2024 | none ahead |
- Named in Sichuan Biokin Pharmaceutical’s own pipeline as
BL-M17D1 (HER2 ADC)
, phase 1, as of Nov 16, 2026 (source).
Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 8, 2024First studies: 2 phase 1 studiesFirst studyNCT06500052, NCT06503783
- Nov 27, 2024Phase 1 study in Breast NeoplasmsNCT06714617 · 3 enrolled · United States
TargetBeta
“HER2 ADC”the company's pipeline, read by Claude · source
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06714617Breast Neoplasms · United States | 1 | Terminated | Jan 30, 2026 | 3 |
| NCT06503783Breast Neoplasms · China | 1 | Recruiting | Aug 2026 | 20 |
| NCT06500052Esophageal Neoplasms · China | 1 | Recruiting | Aug 2026 | 20 |
How it is read
Names in the registry
- “BL-M17D1”, 3 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 2 studies
- Esophageal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.